Related Experiment Videos

Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein

Elena Ostroumov1, Christopher J Hunter

  • 1From the Centre for Bioengineering Research and Education, University of Calgary, Calgary, Alberta, Canada.

Spine
|December 4, 2008
PubMed
Abstract

Insights

The c-Met oncoprotein and its ligand HGF are involved in chordoma malignancy. Targeting this pair may offer new therapeutic strategies for chordoma patients with poor prognoses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Chordomas are rare, malignant bone tumors arising from notochordal remnants.
  • The c-Met oncoprotein and its ligand HGF are implicated in various solid tumors.
  • Understanding c-Met's role in chordoma is crucial due to limited treatment options.

Purpose of the Study:

  • To determine the role of c-Met oncoprotein in chordoma malignancy.
  • To investigate the expression, localization, and function of c-Met and HGF in human chordoma cells.

Main Methods:

  • Established a human sacral chordoma cell line (CCL3).
  • Utilized SDS-PAGE, Western blotting, and immunofluorescence.
  • Performed cell migration functional assays to assess c-Met and HGF activity.

Main Results:

  • HGF binding enhanced intracellular protein tyrosine phosphorylation and c-Met alpha-chain.
  • Immunostaining showed membrane/cytoplasmic localization of c-Met and HGF, shifting to perinuclear upon HGF stimulation.
  • Demonstrated positive chemotactic and migration activity in response to HGF.

Conclusions:

  • The c-Met oncoprotein plays a significant role in chordoma metastasis.
  • The c-Met-HGF signaling pathway is involved in chordoma malignancy.
  • These findings offer promising therapeutic targets for chordoma management.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...